"Our decision to treat typically needs to be made on the balance of likelihood, before the diagnosis of an associated disease process can be fully established, with definitive tests for multiple ...

ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

The Optic Neuritis Treatment Trial (ONTT) found that the best treatment plan for optic neuritis consists of a course of IV steroids, and that oral steroids alone are contraindicated because of an ...

ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and ...

Optic neuritis is a rare autoimmune disease characterized by the inflammation of the optic nerve. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TRE-515 for the ...

Oculis Holding AG recently announced the pricing of a follow-on equity offering to raise approximately US$110 million, issuing 5,432,098 ordinary shares at US$20.25 per share, with the transaction ...

A new therapeutic agent tested in a mouse model of multiple sclerosis (MS) produced anti-inflammatory activity and prevented loss of cells in the optic nerve, according to a new study by researchers ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Fampridine resulted in no significant observed ...

Erythropoietin (EPO), shown in early studies to potentially provide neuroprotection for patients with optic neuritis, failed to provide any significant neuroprotection in comparison with placebo in a ...

"Patients with anti-AQP4-Ab may basically need long-term relapse prevention, because they surely experience much higher relapse activity, with much worse neurological disturbance…In MOGAD patients, ...

Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial Oculis Holding AG ...